Last reviewed · How we verify
NCT06765551: ACTIVATE
AI Based Muscular Ultrasound to Assess Intensive Care Unit-acquired Weakness
trial testing Neuromuscular Ultrasound in Intensive Care Unit-acquired Weakness in 50 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Jena University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 October 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Neuromuscular Ultrasound
Conditions studied
- Intensive Care Unit-acquired Weakness — all drugs for Intensive Care Unit-acquired Weakness →
- Artifical Intelligence — all drugs for Artifical Intelligence →
- Ultrasound — all drugs for Ultrasound →
Sponsor
Jena University Hospital
Who can join
18 and older, any sex, with Intensive Care Unit-acquired Weakness or Artifical Intelligence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this observational case-control study is to investigate, whether artificial intelligence can detect ultrasound-derived imaging characteristics typical for intensive care unit-acquired weakness. The main questions it aims to answer are: 1. Is the evaluation of specific parameters of neuromuscular ultrasound using AI-based image analysis suitable for detecting and monitoring critically ill ICU patients with ICUAW? 2. Do the results of AI-based ultrasound image analysis correlate with: (A) the severity of ICUAW (B) the visual grading of muscle echogenicity (C) the 30- and 90-day-outcome?
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06765551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intensive Care Unit-acquired Weakness
Currently open trials in the same condition.
- NCT05671614 — Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure? · recruiting
Other Jena University Hospital trials
Trials by the same sponsor.
- NCT06355050 — Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer · not yet recruiting
- NCT06749483 — The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units? · recruiting
- NCT06539377 — Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma · NA · not yet recruiting
- NCT07428226 — Serum Bile Acid Profiles in Patients With Intrahepatic Cholestasis of Pregnancy · recruiting
- NCT06534307 — Long-term Follow-up of Children Born in the PETN Studies · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06765551 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jena University Hospital
- Last refreshed: 9 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06765551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing